Business Description
ExpreS2ion Biotech Holding AB
ISIN : SE0008348262
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 33.66 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.17 | |||||
Beneish M-Score | -1.23 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.8 | |||||
3-Year EBITDA Growth Rate | -30.3 | |||||
3-Year EPS without NRI Growth Rate | -22.8 | |||||
3-Year FCF Growth Rate | -51.5 | |||||
3-Year Book Growth Rate | -25 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.75 | |||||
9-Day RSI | 24.14 | |||||
14-Day RSI | 29.19 | |||||
6-1 Month Momentum % | 132.82 | |||||
12-1 Month Momentum % | -39.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.03 | |||||
Quick Ratio | 6.03 | |||||
Cash Ratio | 5.06 | |||||
Days Sales Outstanding | 58.75 | |||||
Days Payable | 627.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.9 | |||||
Shareholder Yield % | -82.22 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.27 | |||||
Operating Margin % | -1503.05 | |||||
Net Margin % | -1296.47 | |||||
FCF Margin % | -1459.6 | |||||
ROE % | -106.54 | |||||
ROA % | -85.1 | |||||
ROIC % | -435.32 | |||||
ROC (Joel Greenblatt) % | -3265.14 | |||||
ROCE % | -112.89 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.89 | |||||
PB Ratio | 1.12 | |||||
Price-to-Tangible-Book | 1.17 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-Forward-EBIT | -0.97 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Forward-EBITDA | -0.97 | |||||
EV-to-Revenue | 2.44 | |||||
EV-to-Forward-Revenue | 5.36 | |||||
EV-to-FCF | -0.18 | |||||
Price-to-Net-Current-Asset-Value | 1.32 | |||||
Price-to-Net-Cash | 1.65 | |||||
Earnings Yield (Greenblatt) % | -585.42 | |||||
FCF Yield % | -140.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ExpreS2ion Biotech Holding AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 7.05 | ||
EPS (TTM) (kr) | -2.027 | ||
Beta | 0 | ||
Volatility % | 147.56 | ||
14-Day RSI | 29.19 | ||
14-Day ATR (kr) | 0.25049 | ||
20-Day SMA (kr) | 2.1556 | ||
12-1 Month Momentum % | -39.31 | ||
52-Week Range (kr) | 0.713 - 5.97 | ||
Shares Outstanding (Mil) | 51.4 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ExpreS2ion Biotech Holding AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ExpreS2ion Biotech Holding AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
ExpreS2ion Biotech Holding AB Frequently Asked Questions
What is ExpreS2ion Biotech Holding AB(OSTO:EXPRS2)'s stock price today?
When is next earnings date of ExpreS2ion Biotech Holding AB(OSTO:EXPRS2)?
Does ExpreS2ion Biotech Holding AB(OSTO:EXPRS2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |